Navigation Links
Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database

umber of significant risks, which include, but are not limited to: the risk of obtaining the necessary regulatory approvals; the risk of whether products result from development activities; the risk of shifts in the regulatory environment affecting sales of Cytogen's products such as third-party payor reimbursement issues; the risk associated with Cytogen's dependence on its partners for development of certain projects, as well as other factors expressed from time to time in Cytogen's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Cytogen's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Cytogen undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact

Cytogen Corporation
Susan M. Mesco, 609-750-8213


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
2. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
3. New Data for Cytogens QUADRAMET Reported at Annual ASCO Meeting
4. Preclinical Data on Cytogens Technology to be Reported at the AACR Annual Meeting
5. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:3/2/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... 2014. Total revenues were $4.3 million for the three ... months ended December 31, 2013.  Net loss was $5.9 ... as compared to a net loss of $5.1 million ... million and net loss was $22.1 million for the ...
(Date:3/2/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... year ended December 31, 2014. Financial highlights for the fourth ... of $5.3 million, or $0.04 per share. This compares to ... million, or $0.19 per share, for the fourth quarter of ... of $75.3 million and a net loss of $68.4 million, ...
(Date:3/2/2015)... -- Vivex Biomedical, Inc., a leading processor of human tissue, ... that it hired Lou Barnes as President ... Biomedical formed UMTB Biomedical as a wholly-owned subsidiary to ... November 2014. UMTB is the oldest tissue bank in ... year veteran of the tissue banking industry, having most ...
Breaking Medicine Technology:DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 3DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 4DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 5DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 6DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 7DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 8DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 9DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 10DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 11DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 12Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 2Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 3
... June 20, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... subsidiary, Watson Laboratories, Inc. – Florida, filed an ... Food and Drug Administration (FDA) seeking approval to ... product is a generic version of GlaxoSmithKline,s AVODART(R), ...
... Findings from three studies conducted by the U.S. Food ... conveyed and displayed in printed drug advertising affects consumer ... ) The studies, designed by experts ... (DDMAC) in the Center for Drug Evaluation and Research, ...
Cached Medicine Technology:Watson Confirms AVODART(R) Patent Challenge 2FDA Examines Ways to Improve Consumer Understanding of Prescription Drug Ads 2FDA Examines Ways to Improve Consumer Understanding of Prescription Drug Ads 3
(Date:3/2/2015)... Portland, OR (PRWEB) March 02, 2015 ... its plan to remake American healthcare. Zoom will ... include 28 neighborhood clinics and advanced care studios ... mental health, emergency services, specialty care and outpatient ... provide on-demand access to almost all healthcare needs ...
(Date:3/2/2015)... Burns Engineering's Lab-to-Lab Calibration Service ... Standard Platinum Resistance Thermometers (SSPRTs) and industrial Resistance ... less . . . guaranteed. Their ... Code 200706-0), ISO 9001 and 17025 Certified and ... -196°C to 500°C, both ITS-90 and Callendar-van Dusen ...
(Date:3/2/2015)... 02, 2015 Representatives with BNatrl ... officially launched a multivitamin supplement that’s specifically designed ... development for BNatrl, said the multivitamin, which launched ... and other world-class athletes. , "Being an avid ... pure whole food multivitamin to improve my performance,” ...
(Date:3/2/2015)... Dinner preparation and meal planning have ... of DinnerDork , a company that specializes ... thousands of busy customers. The company recently responded ... offer a total of 6 diverse meal plan ... recipes and comfort foods; Paleo Palette, which caters ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 A true renaissance ... leader of the 1960s cult rock band Khazad Doom, has ... his determination to persevere despite all odds. His motto throughout ... matter what situation or goal was before him. And that ... is now being passed on to a new generation. , ...
Breaking Medicine News(10 mins):Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 3Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Bnatrl Launches Multivitamin Supplement for Runners 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 3Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 3
... of Boston, a large clinical trial presents that giving ... after all. It has been assumed by some doctors that ... magnesium by infusion after a heart attack. The improvement in ... have had a specific type of heart attack known as ...
... of radiation therapy promises a better result for people ... likely for most of those who develop// Hodgkin's disease. ... long-term complications of conventional radiation treatment. , ,The ... in the usual way. But researchers at Stanford University ...
... is the first treatment to actually slow down Parkinson's ... treatments for Parkinson's disease// can help alleviate the movement ... actually stop the underlying brain damage. In Parkinson's, cells ... brain, are slowly destroyed, leading to a number of ...
... skin from burns and blisters that are a hazard of ... of curries, its distinctive yellow colour. It is long been ... may fight cancer by cutting off the blood supply to ... Texas uncover that curcumin has another potential benefit. Working with ...
... women with a self-attacking antibody are at an increased ... person's own body tissue. //Generally, antibodies fight foreign infections. ... clots, which can lead to an ischemic stroke. ... study to determine the connection of aPL and stroke ...
... or modernization, the Stress on human life has been increasing ... the adoption of a more healthy and peaceful life ... hearts.Most of us get angry for trivial things which does ... enough to cause life threatning cardiac arrest in patients with ...
Cached Medicine News:
...
Inquire...
... a Compact Size , Featuring design concepts ... with Alokas latest proprietary electronic technologies, the ... units suffer from hardware and software limitations ... new standards for whats possible in a ...
... CONMED's family of products allows you to ... generators feature proprietary Energy Synchronous Processing Technology. ... current and voltage in all operational modes. ... to sample current and voltage over 450,000 ...
Medicine Products: